高良姜素对肝癌细胞抑制作用的机制

李程; 张惠文; 容鹏飞

doi:10.3969/j.issn.1001-5256.2020.08.040

高良姜素对肝癌细胞抑制作用的机制

DOI: 10.3969/j.issn.1001-5256.2020.08.040

中南大学湘雅三医院放射科

基金项目:

国家自然科学基金项目(81771827)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 814
- HTML全文浏览量: 59
- PDF下载量: 179
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Mechanism of the inhibitory effect of galangin on hepatoma cells

Department of Radiology, The Third Xiangya Hospital of Central South University

Research funding:

摘要

摘要:
肝细胞癌(HCC)病死率较高,尽管已有较多的治疗手段,但迄今为止HCC的临床治疗效果仍然欠佳,患者预后差。因此,临床上有必要寻找一种治疗HCC的新药以提高患者的生存率。介绍了一种新的抗肿瘤药物高良姜素,其可以通过抑制细胞增殖、促进凋亡、诱导自噬,以及抑制转移等途径发挥抗癌作用。除此之外,高良姜素还可抑制肝癌新生血管形成、逆转多药耐药以及加强药物的协同作用等。因此,认为高良姜素具有广阔的临床应用前景,期待更多的研究聚焦于高良姜素抗肝癌细胞的作用机制,为其临床转化应用提供充分的科学依据。
- 癌,肝细胞 /
- 高良姜素 /
- 肿瘤抑制蛋白质类
Abstract:
The mortality rate of hepatocellular carcinoma(HCC) remains high,and although there have been several treatment methods,HCC patients still have poor treatment outcome and prognosis in clinical practice.Therefore,it is necessary to find a new drug for the treatment of HCC to improve patients' survival rate.This article introduces a new antitumor drug,galangin,which can exert an antitumor effect by inhibiting cell proliferation,promoting apoptosis,inducing autophagy,and inhibiting metastasis.In addition,galangin can also inhibit angiogenesis in liver cancer,reverse multidrug resistance,and enhance the synergistic effect between drugs.Therefore,galangin is believed to have a promising future in clinical practice,and it is expected that more studies will focus on the anti-hepatoma cell mechanism of galangin to provide a scientific basis for the clinical translation of galangin.
- carcinoma,hepatocellular /
- galangin /
- tumor suppressor proteins

HTML全文

参考文献(32)

[1] YANG JD,HAINAUT P,GORES GJ,et al. A global view of hepatocellular carcinoma:Trends,risk,prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.

[2] KOPUSTINSKIENE DM,JAKSTAS V,SAVICKAS A,et al. Flavonoids as anticancer agents[J]. Nutrients,2020,12(2):457.

[3] ZHAO X,ZHANG J. Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells[J]. J Cent South Univ(Med Sci),2015,40(5):479-485.(in Chinese)赵欣，张健．高良姜素对肺癌肿瘤细胞DNA拓扑异构酶的抑制及细胞杀伤作用[J]．中南大学学报(医学版)，2015,40(5):479-485.

[4] XU YF,YAO X. Inhibitory effect and mechanism of galangin on breast cancer metastasis[J]. Chin Tradit Herb Drug,2016,47(10):1731-1739.(in Chinese)许奕夫，姚鑫．高良姜素抑制乳腺癌转移作用机制研究[J]．中草药，2016,47(10):1731-1739.

[5] LEI D,ZHANG F,YAO D,et al. Galangin increases ERK1/2phosphorylation to decrease ADAM9 expression and prevents invasion in A172 glioma cells[J]. Mol Med Rep,2018,17(1):667-673.

[6] ZHOU YH,WEI JF,LI GD,et al. Warburg effect on tumor[J]. J Int Oncol,2017,44(10):762-766.(in Chinese)周宇会，魏九峰，李国东，等．Warburg效应在肿瘤中的研究进展[J]．国际肿瘤学杂志，2017,44(10):762-766.

[7] WANG Y,LIN B,LI H,et al. Galangin suppresses hepatocellular carcinoma cell proliferation by reversing the Warburg effect[J]. Biomed Pharmacother,2017,95:1295-1300.

[8] GWAK J,OH J,CHO M,et al. Galangin suppresses the proliferation ofβ-catenin response transcription-positive cancer cells by promoting adenomatous polyposis coli/Axin/glycogen synthase kinase-3β-independentβ-catenin degradation[J]. Mol Pharmacol,2011,79(6):1014-1022.

[9] MARQUARDT JU,EDLICH F. Predisposition to apoptosis in hepatocellular carcinoma:From mechanistic insights to therapeutic strategies[J]. Front Oncol,2019,9:1421.

[10] LI Y,WANG ZX,WEN H,et al. Endoplasmic reticulum stress signaling pathway and its association with liver diseases[J]. J Clin Hepatol,2020,36(2):464-467.(in Chinese)李姚，王志鑫，温浩，等．内质网应激的信号通路及其与肝脏疾病的关系[J]．临床肝胆病杂志，2020,36(2):464-467.

[11] SU L,CHEN X,WU J,et al. Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress[J]. Food Chem Toxicol,2013,62:810-816.

[12] ZHANG HT,LUO H,WU J,et al. Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway[J]. World J Gastroenterol,2010,16(27):3377-3384.

[13] JIANG W,WU DB,FU SY,et al. Insight into the role of TRAIL in liver diseases[J]. Biomed Pharmacother,2019,110:641-645.

[14] ZHANG HT,WU J,WEN M,et al. Galangin induces apoptosis in hepatocellular carcinoma cells through the caspase 8/tBid mitochondrial pathway[J]. J Asian Nat Prod Res,2012,14(7):626-633.

[15] AKULA SM,ABRAMS SL,STEELMAN LS,et al. RAS/RAF/MEK/ERK,PI3K/PTEN/AKT/m TORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma[J].Expert Opin Ther Targets,2019,23(11):915-929.

[16] LIU Y,MEI XF,WANG J,et al. Influence of galangin on the apoptosis of human hepatoma cells SMMC-7721 throughPI3K/AKT signal pathway[J]. Pharmocol Clin Chin Mater Med,2014,30(1):40-42.(in Chinese)刘影，梅晰凡，王晶，等．高良姜素对人肝癌SMMC-7721细胞PI3K/AKT信号通路的影响[J]．中药药理与临床，2014,30(1):40-42.

[17] YANG S,YANG L,LI X,et al. New insights into autophagy in hepatocellular carcinoma:Mechanisms and therapeutic strategies[J]. Am J Cancer Res,2019,9(7):1329-1353.

[18] WANG Y,WU J,LIN B,et al. Galangin suppresses HepG2cell proliferation by activating the TGF-βreceptor/Smad pathway[J]. Toxicology,2014,326:9-17.

[19] ZHANG H,LI N,WU J,et al. Galangin inhibits proliferation of HepG2 cells by activating AMPK via increasing the AMP/TAN ratio in a LKB1-independent manner[J]. Eur J Pharmacol,2013,718(1-3):235-244.

[20] WANG JY,LI SW,GONG JP,et al. Role of silent information regulator 1 in hepatic ischemia-reperfusion injury[J]. J Clin Hepatol,2019,35(6):1388-1391.(in Chinese)王敬元，李生伟，龚建平，等．沉默信息调节因子1在肝脏缺血再灌注损伤中的作用[J]．临床肝胆病杂志，2019,35(6):1388-1391.

[21] LI X,WANG Y,XIONG Y,et al. Galangin induces autophagy via deacetylation of LC3 by SIRT1 in HepG2 cells[J]. Sci Rep,2016,6:30496.

[22] WEN M,WU J,LUO H,et al. Galangin induces autophagy through upregulation of p53 in HepG2 cells[J]. Pharmacology,2012,89(5-6):247-255.

[23] LI J,XIAO D,LI ZQ,et al. Expression and significance of matrix metalloproteinase 9 gene in hepatocellular carcinoma cell lines and hepatocellular carcinoma tissues[J]. Chin J Public Health Eng,2018,17(3):351-353.(in Chinese)李杰，肖达，李智奇，等．基质金属蛋白酶9基因在肝癌细胞株、肝细胞肝癌组织中的表达及意义[J]．中国卫生工程学，2018,17(3):351-353.

[24] CHIEN ST,SHI MD,LEE YC,et al. Galangin,a novel dietary flavonoid,attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells[J].Cancer Cell Int,2015,15:15.

[25] FODOR D,JUNG I,TURDEAN S,et al. Angiogenesis of hepatocellular carcinoma:An immunohistochemistry study[J].World J Hepatol,2019,11(3):294-304.

[26] HUANG H,CHEN AY,ROJANASAKUL Y,et al. Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis[J]. J Funct Foods,2015,15:464-475.

[27] KASEB AO,HANBALI A,COTANT M,et al. Vascular endothelial growth factor in the management of hepatocellular carcinoma:A review of literature[J]. Cancer,2009,115(21):4895-4906.

[28] YE Q,LIU K,SHEN Q,et al. Reversal of Multidrug resistance in cancer by multi-functional flavonoids[J]. Front Oncol,2019,9:487.

[29] ZHU X,WONG I,CHAN KF,et al. Triazole bridged flavonoid dimers as potent,nontoxic,and highly selective breast cancer resistance protein(BCRP/ABCG2)inhibitors[J]. J Med Chem,2019,62(18):8578-8608.

[30] REN K,ZHANG W,WU G,et al. Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells[J].Biomed Pharmacother,2016,84:1748-1759.

[31] YU S,GONG LS,LI NF,et al. Galangin(GG)combined with cisplatin(DDP)to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways[J]. Biomed Pharmacother,2018,97:213-224.

[32] PATIL S,UJALAMBKAR V,RATHORE A,et al. Galangin loaded galactosylated pluronic F68 polymeric micelles for liver targeting[J]. Biomed Pharmacother,2019,112:108691.

施引文献

资源附件(0)

访问统计